# The Cigna Group (CI) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Providers & Services. Price $282.52, market value $74.7 billion.

## Valuation
- **P/E (trailing): 11.7×** (5-yr avg 15.7×, 3-yr avg 16.9×). The Cigna Group trades at 11.7× trailing earnings, well below its own five-year average of 15.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 8.4×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.10**. A PEG of 0.10 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.3×**. Each dollar of revenue is priced at 0.3×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.7×**. The shares trade at 1.7× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 5.3×**. Enterprise value is 5.3× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Earnings yield: 8.6%**. The inverse of the P/E: 8.6% of the price is earned each year.

## Profitability
- **Operating margin: 3.5%**. 3.5% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 2.2%**. 2.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 14.3%**. 14.3% on shareholders' equity is solid.
- **Return on invested capital: 22.7%**. Return on all capital, debt included, is 22.7%: comfortably above what that capital costs.
- **Return on assets: 4.0%**. Each dollar of assets produces 4.0% of profit.

## Growth
- **Revenue growth (1 yr): 11.2%** (3-yr 15.0%/yr, 5-yr 11.4%/yr). Revenue grew 11.2% over the last year, against 11.4% a year compounded over five years.
- **EPS growth (1 yr): 83.0%** (3-yr 1.2%/yr, 5-yr -0.7%/yr). Earnings per share rose 83.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. The Cigna Group holds more cash than debt.
- **Altman Z-score: 2.69**. A Z-score of 2.69 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.21%** ($6.14 per share, trailing). The Cigna Group yields 2.21%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 27%**. 27% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 20**. 20 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 172.8%/yr** (1-yr 7.9%). The dividend has compounded at 172.8% a year over five years, doubling roughly every 0 years at that pace.

## Analyst view
- **Analyst consensus: buy** (24 analysts). 24 analysts cover The Cigna Group; the consensus is buy, with an average price target of $341.42 (+21% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -5.5%** (YTD 3.8%, 3-mo -2.4%). The shares are down 5.5% over twelve months including dividends.
- **From 52-week high: -10.4%** (18.0% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.21** (volatility 33%). Beta of 0.21 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CI · Page: https://foliofundamentals.com/stocks/ci

Not investment advice.